BST

EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR

Retrieved on: 
Wednesday, April 10, 2024
Q&A, Associate, Oncology, Internet, Doctor of Philosophy, Spacecraft, MD, AACR, HPHA, Phase, ADC, BST, Hematology, ATAC, Annual general meeting

Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.

Key Points: 
  • Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.
  • The event will provide information on Heidelberg Pharma’s lead clinical ATAC product candidate HDP-101 targeting relapsed and refractory multiple myeloma as well as its proprietary ADC toolbox and therapeutic product pipeline.
  • Attendees will have the opportunity to participate in a live Q&A session at the end of the presentation or submit questions in advance of the event.
  • For further information on the R&D webinar, or to register your interest, please contact Optimum Strategic Communications at [email protected] or register using the link below:

Bango PLC ("Bango" or the "Company") 2023 Full Year Results and 2024 Outlook

Retrieved on: 
Monday, April 8, 2024
Annual, DVM, Growth, ARR, NHN Entertainment Corporation, Digital, Wind, Investment, Annual report, The Annual Report, Depreciation, Music, BST, NHN, Video game

And, to transfer the technology developed in the joint venture to Bango and NHN so both can use it without restriction in their respective core businesses.

Key Points: 

ORYZON to Provide Corporate Progress Updates at Several Events in April

Retrieved on: 
Friday, April 5, 2024
Conference, Biotechnology, Genomics, LSX, BST, Pharma, Cryptocurrency

Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.

Key Points: 
  • Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies.
  • The company will hold one-on-one meetings with pharmaceutical companies.
  • Oryzon will take part in the keynote plenary panel entitled “The inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future” on April 29 at 16:20 BST.
  • Click on the link for more info about the LSX World Congress 2024

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

Retrieved on: 
Friday, April 5, 2024
TME, Development, FAP, Doctor of Philosophy, Patient, Doxorubicin, Tumor microenvironment, Royal Marsden Hospital, MD, AACR, Research and development, Institute of Cancer Research, Poster, Heterotrimeric G protein, BST, AIM, Fine chemical

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

Key Points: 
  • Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
  • A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/ .
  • Christina Coughlin will provide a video presentation overview examining the data presented in the poster.
  • Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data.

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 3, 2024
Webcast, Fireside, BST, Conference, Fireside chats

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST.

Key Points: 
  • LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST.
  • A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors .
  • An archived replay of the webcast will be available on the Company’s website for two weeks following the live event.

Skoll Foundation Announces the Winners of 2024 Skoll Award for Social Innovation

Retrieved on: 
Tuesday, April 2, 2024
Environmental, Social and Governance (ESG), Public Policy, Media, Children, Communications, Public Safety, Transport, Elections, Campaigns, Other Technology, Other Philanthropy, Government, Technology, Public Transport, Primary, Secondary, Education, Fund Raising, Foundation, Women, General Health, Men, Health, Social Services, Family, Social Activism, Professional Services, Philanthropy, Consumer, Skoll Foundation, Democracy, Organization, Social innovation, Farmer, Sköll, Hunger, Name, School, Public, Research, Policy, Child, Native, Death, Poverty, New Theatre, Jeffrey Skoll, Malnutrition, Creativity, Safety, BST, Social change, Movement, Parent, Fatality, Violence, Food, Renewable energy

The Skoll Foundation has announced the four organizations that will receive the 2024 Skoll Award for Social Innovation, which highlights leaders and organizations that advance transformational social change around the world.

Key Points: 
  • The Skoll Foundation has announced the four organizations that will receive the 2024 Skoll Award for Social Innovation, which highlights leaders and organizations that advance transformational social change around the world.
  • Every year, the Skoll Award for Social Innovation recognizes exemplary leaders and organizations creating a more sustainable, peaceful, and prosperous world.
  • The Awardees will be celebrated during the 21st Skoll World Forum at the 2024 Awards for Social Innovation Ceremony, taking place on Thursday, April 11, 4:30-6 p.m. BST at the New Theatre in Oxford, England and virtually.
  • “Global challenges are mounting at an increasing pace,” said Don Gips, CEO of the Skoll Foundation.

Ardagh Metal Packaging S.A. Q1 2024 Results and Investor Call Notification

Retrieved on: 
Friday, March 22, 2024
BST

LUXEMBOURG, March 22, 2024 /PRNewswire/ -- Ardagh Metal Packaging S.A. will host its First Quarter 2024 earnings call on Thursday, April 25, 2024.

Key Points: 
  • LUXEMBOURG, March 22, 2024 /PRNewswire/ -- Ardagh Metal Packaging S.A. will host its First Quarter 2024 earnings call on Thursday, April 25, 2024.
  • A results release will be posted to our website at midday BST (07:00 EDT) on April 25, 2024, at https://www.ardaghmetalpackaging.com/investors
    An investor webcast and conference call will be held at 14:00 BST (9:00 EDT) on April 25, 2024.
  • A full replay of the presentation will also be available at the same link shortly after the conclusion of the live presentation.

Director/PDMR Shareholding (Correction)

Retrieved on: 
Wednesday, March 13, 2024
BST

This statement replaces the PDMR notification issued on 27 November 2023 at 13:52 BST under EQS News ID 1782689:

Key Points: 
  • This statement replaces the PDMR notification issued on 27 November 2023 at 13:52 BST under EQS News ID 1782689:
    to correct an error in the price paid for the purchase of 439 shares from £0.92 to £0.9186; and
    to include a second purchase of 68 shares at £0.9186 each.
  • All other details remain as previously announced.
  • The full amended text as corrected is included below.

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, OXB, Growth, Transaction, CDMO, European, COVID-19, Oxford Biomedica, BST, AAV, Lentivirus, VWAP

Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024.

Key Points: 
  • Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024.
  • In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million.
  • Operating EBITDA loss for the second half of 2023 is on track to be approximately £10 million better than the first half, as previously guided.
  • A briefing for investors and analysts will take place at 13:00 BST / 08:00 ET at One Moorgate Place, London, EC2R 6EA.

MultiPlan Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 29, 2024
Software, Networks, Professional Services, Fintech, Data Management, Payments, Technology, Health Technology, Health Insurance, Data Analytics, Insurance, Practice Management, Health, Acquisition, Theory, Multiplan, Note, Medicare Advantage, Growth, Adjustment, Risk, MPLN, Medicare, BST, PIK, Cryptocurrency

MultiPlan Corporation (“MultiPlan” or the “Company”) (NYSE: MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • MultiPlan Corporation (“MultiPlan” or the “Company”) (NYSE: MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • “As we close out 2023, I am very encouraged by the progress we have made toward our long-term goal of transforming our business,” said Dale White, CEO of MultiPlan.
  • Net loss for full year 2023 of $91.7 million, compared to net loss of $572.9 million for full year 2022.
  • The Company processed $43.4 billion in medical charges during the fourth quarter 2023, identifying potential medical cost savings of approximately $5.9 billion.